| Similar Articles |
|---|
 |
The Motley Fool
March 28, 2008
Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug.   |
Chemistry World
July 31, 2012
Andrew Turley |
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January. |
The Motley Fool
June 9, 2011
Brian Orelli |
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. |
Managed Care
June 2004
Thomas Morrow |
Laronidase Opens Door To Treat Other Rare Disorders The release of alpha-L-iduronidase also demonstrates the wave of future treatments for many other mucopolysaccharidosis (MPS) diseases. |
Pharmaceutical Executive
February 1, 2014
Ben Comer |
The Active Patient: Faces Of Change Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease and having access to social media. |
Chemistry World
June 9, 2015
Phillip Broadwith |
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
American Family Physician
June 15, 2002
Stephanie C. Brundage |
Preconception Health Care Appropriate preconception health care improves pregnancy outcomes. |
The Motley Fool
June 9, 2011
Brian D. Pacampara |
Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment. |
Managed Care
January 2001 |
Humana Reports Rosy Outcomes For Complex DM Humana and Accordant Health Services report achieving significant reductions of complications among patients with multiple sclerosis, lupus, and cystic fibrosis... |
Salon.com
November 17, 1999
Kristi Coale |
Playing God Scary eugenics documents from the turn of the century shine a disturbing light on ethical dilemmas raised by genetic testing. |
Popular Mechanics
January 2010
Amber Angelle |
How to Create a Designer Baby Women undergoing in vitro fertilization could one day choose to have a baby boy with perfect vision, an aptitude for sports and a virtual lock on avoiding colon cancer. |
The Motley Fool
March 20, 2009
Brian Orelli |
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
HBS Working Knowledge
June 5, 2006
Porter & Olmsted Teisberg |
Using Competition to Reform Healthcare The new book Redefining Health Care: Creating Value-Based Competition on Results, takes a systemic approach to healthcare reform. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
Chemistry World
February 25, 2014
Charlie Quigg |
Cystic fibrosis treatment clears the way Stabilizing a mucus attacking enzyme with cross-links could allow it to be delivered orally to fight infections in cystic fibrosis patients. |
The Motley Fool
June 29, 2009
Brian Orelli |
Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug. |
The Motley Fool
January 3, 2011
Travis Hoium |
Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning. |
Chemistry World
December 4, 2014
Anthony King |
Cystic Fibrosis Foundation sells drug royalty rights for $3.3bn The Cystic Fibrosis Foundation has sold royalty rights to treatments developed with support from its 'venture philanthropy' model. |
Reason
November 2002
Cathy Young |
Dad Blood If DNA tests prove that you're not your children's father, do you still owe child support? |
The Motley Fool
July 22, 2011
Luke Timmerman |
Bristol-Myers Acquires Amira Pharmaceuticals, Scoops Up Lung Drug BMY looks to fulfill the need for a lung drug. |
The Motley Fool
September 24, 2007
Jack Uldrich |
Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note. |
BusinessWeek
May 9, 2005 |
A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon. |
Bio-IT World
June 2005 |
News Blast Gene Alliance... CF Kit Cleared... Brain Power... |
American Family Physician
October 1, 2000
Rochelle Scheib, M.D. |
Photo Quiz Diagnose this illness: Facial Masses |
The Motley Fool
October 28, 2011
Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. |
Salon.com
October 14, 1999
Dawn MacKeen |
Woe is HMO Proponents of liability legislation argue that the only way to change managed care's behavior is to threaten it with lawsuits. |
Managed Care
April 2001
Patrick Mullen |
Interview: Alan F. Holmer With the ever-rising cost of prescription drugs generating an outcry to reform Medicare, PhRMA's president finds himself in the eye of the storm... |
Chemistry World
August 29, 2014
Sarah Houlton |
Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion. |
The Motley Fool
September 4, 2008
Brian Lawler |
Sitting Tight in September This month, several drugmakers will hear about compounds awaiting approval, so we can expect some volatility in their share prices. Read on to see who's awaiting FDA news. |
The Motley Fool
July 21, 2010
Ryan McBride |
Eli Lilly Pays up to $380M for Alnara Pharma Indianapolis-based Lilly is paying $180 million upfront for all of Alnara's shares, and shareholders are eligible for as much as $200 million in additional payments depending on whether certain regulatory and commercial milestones are met. |
Chemistry World
February 22, 2011
Amaya Camara-Campos |
Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs. |
